SaVipharm receives the Third Class Labour Order. (Photo courtesy of SaVipharm) HCM City (VNA) - SaVi Pharmaceutical Joint Stock Company (SaVipharm) held a ceremony on March 6 to receive the Labour Order, third class, and inaugurate a high-tech Research and Development Centre along with a national modern medicine distribution system.
SaVipharm, established in 2005, has always paid attention to scientific and applied research. It has spent 5 percent of total revenue each year to this purpose.
The company has researched and developed 12 types of medicines and submitted more than 400 sets of generic medicine documents to the Ministry of Health’s Drug Administration of Vietnam. It has also been granted over 300 new registration numbers for licensed manufacturing, which has contributed to increasing the market share of domestically-manufactured medicine to 50 percent and ensuring sufficient medicines for disease prevention and treatment of the people.
SaVipharm inaugurates High-Tech Research and Development Center and Nationwide Modern Medicine Distribution System. (Photo courtesy of SaVipharm) SaVipharm is one of the first Vietnamese pharmaceutical companies to be assessed and awarded the Certificate of Science and Technology Company for over 230 products.
With an average production growth of 20 percent a year, SaVipharm turned out 465.6 million and 533.4 million tablets in 2020 and 2021 respectively. Its annual revenue has increased by over 15 percent a year, compared to the pharmaceutical sector’s average growth of 8 – 10 percent.
SaVipharm has been a pioneer in exporting medicines to Japan since 2011. In addition, its medicines have been supplied to ASEAN countries like Malaysia, Cambodia and Laos.
SaVipharm is one of the first Vietnamese pharmaceutical companies to obtain both European and Japanese GMP certificates. The OSD pharmaceutical factory of SaVipharm is equipped with SCADA synchronous and up-to-date manufacturing lines and devices and meets two global standards.
Leaders visit the High-Tech Research and Development Center. (Photo courtesy of SaVipharm) The High-Tech R&D Centre has been invested and operated by SaVipharm with total investment capital of 200 billion VND. All the devices and technologies are imported from G7 countries, including labs, pilot-scale devices and technologies, and equipment for commercial manufacturing. The facility is designed for researching and developing high quality medicine groups (pellet and microgranular technologies), biomedical products, and new generation medicines for cancer treatment.
SaVipharm has invested in one distribution centre in Ho Chi Minh City; four supply centres for other regions and branches using WMS, DMS, Barcode and TMS software; automatic sorting and routing lines; and temperature controlled transport vehicles. Therefore, this system has helped improve the quality and effectiveness of medicine supply throughout the nation and received high appreciation from hospitals, local and foreign partners, and pharmacies.
Member of the Party Central Committee, member of the National Assembly Standing Committee and Chairman of the National Assembly's Committee on Science, Technology and Environment Le Quang Huy. (Photo courtesy of SaVipharm) Responding to the appeal and following the directions of the Prime Minister during his inspection of epidemic prevention and control at SaVipharm on July 11 2021, the company has overcome challenges and achieved great success in developing high quality medicines for healthcare of the people.
SaVipharm has successfully researched and invented a medicine for COVID-19 treatment and is completing necessary procedures and conditions to put it into mass manufacturing. Furthermore, SaVipharm has studied and developed four types of special medicines that contain microgranular ingredients generated by the equipment and technologies of the Hi-tech R&D Centre. The company is initiating investment, business and manufacturing strategies for the period of 2021-2025 with a vision to 2030, and executing the applied research of vital high-tech medicine groups to satisfy the requirements for epidemic prevention and control in Vietnam.
Deputy Minister of Health Nguyen Truong Son (Photo: VNA) Moreover, SaVipharm is finalising legal procedures for commencement of an European GMP-standardized high-tech cancer medicine factory equipped with two automatic OSD medicine manufacturing lines.
Through 15 years of formation and development as well as the solidarity and endeavour of all employees, SaVipharm has achieved remarkable results in science and technology, investment and development, manufacturing and supply and become one of the leading pharmaceutical companies in Vietnam./.
